Methylene blue is used to treat methemoglobinemia.

Methylene blue is used to treat methemoglobinemia.

• A. True
• B. False
• C. Only in children
• D. Not recommended in any circumstance

Answer: (A)

Methemoglobinemia is caused when iron in hemoglobin is oxidized to the ferric (Fe3+) state, which cannot bind oxygen effectively and shifts the oxygen-hemoglobin dissociation curve unfavorably. Methylene blue directly helps reverse this defect by acting as an artificial electron donor in the body's NADPH-dependent methemoglobin reductase pathway. When given IV, methylene blue is reduced to leucomethylene blue by NADPH. Leucomethylene blue then donates electrons to methemoglobin, converting the Fe3+ back to the functional Fe2+ state, restoring hemoglobin’s oxygen-carrying capacity and improving oxygen delivery rapidly. The typical dose is about 1–2 mg/kg IV over a few minutes, with a possible repeat dose if methemoglobinemia persists, usually not exceeding a total of around 7 mg/kg. It’s important to recognize situations where its use requires caution: in G6PD deficiency, NADPH production is impaired, so methylene blue may be ineffective and can provoke hemolysis, so alternatives are preferred. It can also interact with serotonergic medications because methylene blue has monoamine oxidase–inhibiting activity, raising the risk of serotonin syndrome; therefore such interactions must be considered before use. When used appropriately, methylene blue is a rapid and effective treatment for clinically significant methemoglobinemia.

Methemoglobinemia is caused when iron in hemoglobin is oxidized to the ferric (Fe3+) state, which cannot bind oxygen effectively and shifts the oxygen-hemoglobin dissociation curve unfavorably. Methylene blue directly helps reverse this defect by acting as an artificial electron donor in the body's NADPH-dependent methemoglobin reductase pathway. When given IV, methylene blue is reduced to leucomethylene blue by NADPH. Leucomethylene blue then donates electrons to methemoglobin, converting the Fe3+ back to the functional Fe2+ state, restoring hemoglobin’s oxygen-carrying capacity and improving oxygen delivery rapidly.

The typical dose is about 1–2 mg/kg IV over a few minutes, with a possible repeat dose if methemoglobinemia persists, usually not exceeding a total of around 7 mg/kg. It’s important to recognize situations where its use requires caution: in G6PD deficiency, NADPH production is impaired, so methylene blue may be ineffective and can provoke hemolysis, so alternatives are preferred. It can also interact with serotonergic medications because methylene blue has monoamine oxidase–inhibiting activity, raising the risk of serotonin syndrome; therefore such interactions must be considered before use. When used appropriately, methylene blue is a rapid and effective treatment for clinically significant methemoglobinemia.